• DOI:10.1097/01.CCM.0000253395.70708.AC
• Corpus ID: 27217733

Topical chlorhexidine for prevention of ventilator-associated pneumonia: A meta-analysis*

@article{Chlebicki2007TopicalCF,
  title={Topical chlorhexidine for prevention of ventilator-associated pneumonia: A meta-analysis*},
  author={Maciej Piotr Chlebicki and Nasia Safdar},
  journal={Critical Care Medicine},
  year={2007},
  volume={35},
  pages={595-602}
}

• M. P. Chlebicki, N. Safdar
• Published 1 February 2007
• Medicine
• Critical Care Medicine

Objective:To assess the efficacy of topical chlorhexidine for prevention of ventilator-associated pneumonia (VAP) in a meta-analysis. Data Source:Computerized PubMed and MEDLINE search supplemented by manual searches for relevant articles. Study Selection:Randomized controlled trials evaluating efficacy of topical chlorhexidine applied to the oropharynx vs. placebo or standard care for prevention of VAP. Data Extraction:Data were extracted on patient population, inclusion and exclusion criteria, diagnostic criteria for VAP, form and concentration of topical chlorhexidine used, incidence of VAP, and overall mortality. Data Synthesis:Data on incidence of VAP and mortality were abstracted as dichotomous variables. Pooled estimates of the relative risk and 95% confidence intervals were obtained using the DerSimonian and Laird random effects model and the Mantel-Haenszel fixed effects model. Heterogeneity was assessed using the Cochran Q statistic and I2. Subgroup analyses were used to explore heterogeneity. Results:Seven randomized controlled trials met the inclusion criteria. Topical chlorhexidine resulted in a reduced incidence of VAP (relative risk, 0.74; 95% confidence interval, 0.56–0.96; p = .02) using a fixed effects model. Using the more conservative random effects model, the point estimate was similar (relative risk, 0.70; 95% confidence interval, 0.47–1.04; p = .07), but the results failed to achieve statistical significance. The I2 test showed moderate heterogeneity. Subgroup analysis showed that the benefit of chlorhexidine was most marked in cardiac surgery patients (relative risk, 0.41; 95% confidence interval, 0.17–0.98; p = .04). There was no mortality benefit with chlorhexidine although the sample size was small. Conclusions:Our analysis showed that topical chlorhexidine is beneficial in preventing VAP; the benefit is most marked in cardiac surgery patients. A large randomized trial is needed to determine the impact of topical chlorhexidine on mortality.